Computational Investigation of Marine Bioactive Compounds Reveals Frigocyclinone as a Potent Inhibitor of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) Targets
Nirmaladevi Ponnusamy
, Rajasree Odumpatta, Pavithra Damodharan and Mohanapriya Arumugam*Department of Biotechnology, Vellore Institute of Technology, Vellore, 632014-India.
Corresponding Author E-mail: mohanapriyaa@vit.ac.in
Abstract: In the present study, in silico analysis was employed to identify the action of marine bioactive compounds against KSHV targets. Virulence factor analysis of KSHV from literature review, three proteins LANA1, vIRF3/LANA2 and PF-8 were identified as putative drug targets. The quality of protein structures play a significant role in the experimental structure validation and prediction, where the predicted structures may contain considerable errors was checked by SAVES v5.0 servers. By virtual screening four potential bioactive compounds Ascorbic acid, Salicylihalamide A, Salicylihalamide B and Frigocyclinone were predicted. One of the potential compounds of Frigocyclinone has acting against KSHV proteins. Hence, determined as the good lead molecule against KSHV. Molecular dynamic simulation studies revealed the stability of LANA1- Frigocyclinone complex and it could be a futuristic perspective chemical compound for Kaposi’s sarcoma.
Keywords: Anti-Tumor Property and Angucyclinone Derivatives; Binding Energy; Bioactive Compounds; Frigocyclinone; KSHV Back to TOC